Lexeo Therapeutics (LXEO) announced that Dr. Kyle Rasbach has been appointed Chief Financial Officer, CFO, effective immediately. Most recently, Dr. Rasbach served as the Chief Business Officer at Zentalis Pharmaceuticals (ZNTL)
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics files $300M mixed securities shelf
- Four new option listings and one option delisting on December 10th
- Lexeo Therapeutics Advances Cardiac Portfolio Amid Financial Report
- Lexeo Therapeutics price target raised to $23 from $21 at H.C. Wainwright
- Lexeo Therapeutics price target raised to $25 from $23 at Chardan